Prognostic role of tumor size in T1 HER2-positive breast cancers treated with adjuvant trastuzumab
We have read with great interest the recent study by Rodrigues et al. [1] , in which the efficacy of trastuzumab in adjuvant setting was retrospectively evaluated in 276 cases of T1abN0 HER2-positive breast carcinomas obtained from eight French cancer centers. Authors found that the addition of trastuzumab to adjuvant chemotherapy treatment was associated with a significantly reduced risk of recurrence independently of tumor size. As guidelines point mainly to the size of T1 HER2-positive tumors as the basis for inclusion of trastuzumab in adjuvant treatment [2] [3] [4] , we would like to share the results on tumor size obtained evaluating 498 T1 HER2-positive tumors treated with chemotherapy plus trastuzumab in adjuvant setting between 2005 and 2009, deriving from our recently published multicenter Italian observational study [5] .
Our series included 41 (8.2%) T1a/T1micro, 111 (22.3%) T1b and 346 (69.5%) T1c. The three T1 subgroups did not significantly differ in the distribution of estrogen-receptor (ER)-positive tumors, grade III tumors, presence of intraductal component, multifocality, vascular invasion or median age. In addition, more than 50% of the cases for each T1 category were node-negative, independently of tumor size. Only the percentage of progesterone-receptor (PgR)-positive cases was significantly higher in the T1c group (53.4% versus 42.5% T1a/ T1micro and 42.0% T1b, P = 0.047). Almost all patients (98.6%) received trastuzumab every 3 weeks, while 1.4% received weekly trastuzumab; 421 (84.5%) patients completed 1-year trastuzumab treatment. Chemotherapy regimens were distributed among patients as follows: 229, anthracyclines alone; 195, anthracyclines plus taxanes; 16, taxanes alone and 7, other regimens, with no significant differences between the three T1 subgroups. The remaining 51 cases were missing. Anthracyclines plus taxanes were administered more frequently in N+ than N− patients (61.2% versus 22.0%, P < 0.001). Hormone therapy was used in 284 patients, 183 of whom received aromatase inhibitors (no significant differences between the T1 groups).
The median follow-up was 33.2 months and the overall frequency of relapses was 34 (6.8%) (9 in N0 and 25 in N+ patients), of which 9 were local, 1 contralateral and 24 distant. Relapse onset analysis revealed no statistically significant differences in relapse rate among the T1a/T1micro, T1b and T1c groups, and no statistically significant association between tumor size and disease-free survival (DFS) was found (Table 1) . Instead, nodal status, tumor grade, ER-and PgR-expression showed a raw association with DFS ( The histone deacetylase inhibitor panobinostat is active in patients with advanced pretreated ovarian sex-cord tumors
Ovarian sex cord tumors (OSCT) account for only 7% of ovarian malignancies and include granulosa cell tumor (GCT), Sertoli-Leydig cell tumor, fibrothecomatous tumor and OSCT not otherwise specified. These tumors often have an indolent clinical behavior and are generally associated with favorable prognosis. However, once the tumor has spread outside the pelvis (stages III and IV), 5-year survival is limited and varies between 0 and 20% depending on histological subgroups [1] . Surgery is the cornerstone of therapy for localized disease and probably has a role in advanced disease as well. Patients with metastatic and/or recurrent disease that are not amenable to complete surgical excision are usually treated with first-line cisplatin-based chemotherapy (bleomycin, etoposide and cisplatin or carboplatin and paclitaxel) [2] . However, data to guide further therapy beyond are limited. Aside from the recently reported FOXL2 mutation found in GCT, knowledge regarding the biology of OSCT is limited, although their natural history suggests a different biology from that of carcinomas. We report here on the interesting activity of the histone deacetylase (HDAC) inhibitor panobinostat (formerly LBH589, Novartis, Basel, Switzerland) in this rare disease. HDACs were discovered through their HDAC activity, but other substrates include the chaperone protein HSP90, p53 and tubulins. Activity of vorinostat, an HDAC inhibitor, had been observed in a patients with granulosa cell tumor treated in a phase 1 trial [3] and prompted us to further explore the activity of this class of compound in OSCT.
The patients were enrolled in a phase II trial and provided written informed consent before any trial-related procedure. This trial enrolled mainly patients with soft tissue sarcoma and has been published elsewhere [4] , but also allowed the enrollment of patients with advanced OSCT tumors previously treated with at least one line of cisplatin-containing chemotherapy (trial number NCT01136499). Details regarding trial design were previously described [4] . Briefly, patients were required to have RECISTdefined disease progression before study entry. Computed tomography scans were repeated every 6 weeks for the first 12 weeks and every 8 weeks thereafter. Panobinostat (LBH589) was administered orally, at doses of 40 or 20 mg thrice a week (Monday, Wednesday, Friday) on 28-day cycles. Dose interruption and dose reductions were allowed to manage toxicity.
Five patients with advanced pretreated OSCT were recruited, their age ranged from 35 to 65 years (Table 1 ). All patients had recurrent disease following surgery and had received at least one line of prior chemotherapy for advanced disease (number of prior lines of chemotherapy: 1-4, Table 1 ). Safety of panobinostat was not different from that observed in patients with sarcoma 4 and adverse events consisted mainly of hematological toxicity (anemia, thrombocytopenia), gastrointestinal disorders (nausea and diarrhea) and fatigue. All five patients required at least one dose reduction at some point in the study, mostly because of thrombocytopenia. None of these patients had significant electrocardiogram (ECG) findings (e.g. corrected QT
